Invest in the Future of Disease Interception.
Building the AI-powered molecular intelligence platform for the next generation of precision healthcare.
Kihealth is developing a scalable healthcare technology platform designed to transform disease detection, prediction, and prevention through molecular diagnostics, artificial intelligence, and predictive clinical intelligence.
- Round
- Series A
- Target Launch
- Late 2026
- Investor Type
- Accredited Only
- Structure
- Preferred Equity
- Min. Commitment
- Available on request
A platform investment — not a single-product bet.
Kihealth is building the molecular intelligence layer powering an expanding family of diagnostics, monitoring tools, and predictive applications across the world's largest disease burdens.
Kihealth is building the InterceptIQ™ platform — a scalable technology foundation capable of supporting multiple diagnostic products and disease categories.
Value is engineered across clinical diagnostics, AI-powered healthcare, pharmaceutical partnerships, research services, employer health, international expansion, and software-enabled care.
One technology platform powers a growing family of companies spanning metabolic disease, neurodegeneration, oncology, commercial healthcare, international markets, and research.
The upcoming Series A will accelerate commercialization, platform expansion, clinical validation, regulatory milestones, and strategic partnerships.
Eight reasons institutional investors are paying attention.
Series A capital deployed across eight strategic priorities.
Each allocation compounds the value of the InterceptIQ™ platform — building durable infrastructure rather than funding a single product cycle.
Specific allocation percentages will be shared in the confidential Series A information package.
A staged roadmap from financing to category-defining enterprise value.
Capitalize the platform for scale.
Expand lab operations and go-to-market.
Advance flagship programs through regulatory milestones.
New disease verticals on the InterceptIQ™ foundation.
Deepen the Intercept Score™ and decision support.
Oncology, neurology, metabolic, and beyond.
Pharma, payer, and health-system alliances.
Europe and global market entry.
A category-defining healthcare technology company.
One platform. Six operating companies. Multiple markets.
InterceptIQ™ is the strategic platform asset. The ecosystem extends its reach across diagnostics, therapeutics-adjacent research, commercial healthcare, international markets, and education.
Six reasons this platform is built to compound.
Patented InterceptIQ™ foundation across multiple modalities.
Continuous learning models that compound in value with data.
Trillion-dollar disease burdens across global healthcare.
Diagnostics, pharma partnerships, software, and services.
Six operating entities sharing one strategic platform.
Building the infrastructure layer for predictive healthcare.
At the intersection of healthcare's fastest-growing sectors.
Kihealth is positioned across multiple converging markets — each compounding into the platform's long-term commercial opportunity.
Healthcare is shifting toward earlier, more personalized diagnosis.
Predictive analytics and clinical decision support drive adoption.
Growing from ~$11B in 2026 alongside precision therapeutics.
Fueled by AI, genomics, biomarker discovery, and prevention.
Positioned at the Convergence of Healthcare's Largest Growth Markets
Rather than participating in a single market, Kihealth is building the platform at the intersection of multiple high-growth healthcare sectors — creating diversified opportunities for commercialization, partnerships, and long-term value creation.
Building the infrastructure for the next generation of healthcare.
As healthcare shifts from reactive treatment toward predictive, preventative, and precision medicine, platforms integrating molecular diagnostics, artificial intelligence, and longitudinal clinical intelligence will become foundational infrastructure for the future of care.
Building the future of predictive healthcare.
Kihealth believes healthcare is moving from reactive treatment toward predictive, preventative, and precision medicine. Through the InterceptIQ™ platform, artificial intelligence, and an expanding ecosystem of focused healthcare companies, we are building the infrastructure to support that transformation.
Join the next phase of growth.
We welcome conversations with qualified investors, strategic partners, and healthcare-focused institutions interested in learning more about Kihealth's upcoming Series A financing.
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer will be made only by means of confidential offering materials to qualified accredited investors in accordance with applicable securities laws. Forward-looking statements regarding Kihealth's platform, pipeline, regulatory plans, and financing activities are subject to risks and uncertainties; actual results may differ materially.